Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities.

Li YB, Wang ZQ, Yan X, Chen MW, Bao JL, Wu GS, Ge ZM, Zhou DM, Wang YT, Li RT.

Cancer Lett. 2013 Oct 28;340(1):88-96. doi: 10.1016/j.canlet.2013.07.005. Epub 2013 Jul 12.

PMID:
23856030
2.

BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities.

Sun QM, Miao ZH, Lin LP, Gui M, Zhu CH, Xie H, Duan WH, Ding J.

Cancer Biol Ther. 2009 Sep;8(17):1640-7. Epub 2009 Sep 6.

PMID:
19625781
3.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

4.

Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.

Zhong ZF, Hoi PM, Wu GS, Xu ZT, Tan W, Chen XP, Cui L, Wu T, Wang YT.

J Ethnopharmacol. 2012 Jun 1;141(2):721-7. doi: 10.1016/j.jep.2011.08.052. Epub 2011 Sep 3.

PMID:
21911050
5.

KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.

Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.

Cancer Lett. 2013 May 10;332(1):74-82. doi: 10.1016/j.canlet.2013.01.015. Epub 2013 Jan 21.

PMID:
23348694
6.

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, Zuo J, Jiang H, Geng M, Ding J.

PLoS One. 2011;6(7):e21487. doi: 10.1371/journal.pone.0021487. Epub 2011 Jul 18.

7.

Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.

Fernand VE, Losso JN, Truax RE, Villar EE, Bwambok DK, Fakayode SO, Lowry M, Warner IM.

Chem Biol Interact. 2011 Jul 15;192(3):220-32. doi: 10.1016/j.cbi.2011.03.013. Epub 2011 Mar 30.

PMID:
21457705
8.

Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells.

Zhao D, Qin C, Fan X, Li Y, Gu B.

Eur J Pharmacol. 2014 Jan 15;723:360-7. doi: 10.1016/j.ejphar.2013.10.069. Epub 2013 Nov 13.

PMID:
24239714
9.

Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.

Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, Yang DP, Chen YL, Shen JG, Chen JP.

Breast Cancer Res Treat. 2012 Aug;134(3):943-55. doi: 10.1007/s10549-012-1977-9. Epub 2012 Feb 21.

10.

In vitro and in vivo anti-angiogenic activities of Panduratin A.

Lai SL, Cheah SC, Wong PF, Noor SM, Mustafa MR.

PLoS One. 2012;7(5):e38103. doi: 10.1371/journal.pone.0038103. Epub 2012 May 30.

11.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

13.

5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway.

Zhu W, Fu A, Hu J, Wang T, Luo Y, Peng M, Ma Y, Wei Y, Chen L.

Exp Mol Med. 2011 Mar 31;43(3):146-52. doi: 10.3858/emm.2011.43.3.017.

15.

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.

BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188.

16.

PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.

Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.

PMID:
21181437
17.

Polyphyllin D, a steroidal saponin from Paris polyphylla, inhibits endothelial cell functions in vitro and angiogenesis in zebrafish embryos in vivo.

Chan JY, Koon JC, Liu X, Detmar M, Yu B, Kong SK, Fung KP.

J Ethnopharmacol. 2011 Sep 1;137(1):64-9. doi: 10.1016/j.jep.2011.04.021. Epub 2011 May 31.

PMID:
21658438
18.

Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo.

He MF, Gao XP, Li SC, He ZH, Chen N, Wang YB, She JX.

Eur J Pharmacol. 2014 Oct 5;740:240-7. doi: 10.1016/j.ejphar.2014.07.034. Epub 2014 Jul 24.

PMID:
25064343
19.

Synthesis and antiangiogenic activity of novel gambogic acid derivatives.

Chen T, Zhang RH, He SC, Xu QY, Ma L, Wang GC, Qiu N, Peng F, Chen JY, Qiu JX, Peng AH, Chen LJ.

Molecules. 2012 May 25;17(6):6249-68. doi: 10.3390/molecules17066249.

20.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

Items per page

Supplemental Content

Write to the Help Desk